

Statement of Standalone Unaudited Results for the Quarter & Half year ended 30.09.2023							
							(In Rs. Thousands)
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	40680.96	14001.43	21338.18	54682.38	36891.73	154243.45
II.	Other income	93.34	136.95	77.21	230.30	161.21	397.21
III.	Total Income (I+II)	40774.30	14138.38	21415.39	54912.68	37052.94	154640.66
IV.	Expenses						
	(a) Cost of materials consumed	13824.44	2827.89	4923.70	16652.33	17725.61	55136.35
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	13525.27	1460.76	3405.12	14986.03	-4590.51	-210.00
	(d) Employee benefits expense	8489.54	7249.92	5121.32	15739.46	10602.38	28017.97
	(e) Finance Costs	1812.56	1217.14	1170.99	3029.70	2085.04	3690.54
	(f) Depreciation and amortisation expense	4322.62	4187.81	4666.53	8510.44	9280.61	18785.72
	(g) Other expenses	12484.09	8983.79	9153.53	21467.88	22156.50	48758.86
	Total expenses (IV)	54458.52	25927.32	28441.19	80385.84	57259.64	154179.43
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	461.23
VI.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII.	Profit/ (Loss) before tax (V-VI)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	461.23
VIII.	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	1850.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	348.09
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	-1040.68
X.	Profit/(loss) from discontinued operations						
XI.	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00		0.00	0.00	0.00	0.00
XIII.	Profit (Loss) for the period (IX+XII)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	-1040.68
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00		0.00	0.00	0.00	0.00
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-13684.23	-11788.94	-7025.81	-25473.17	-20206.70	-1040.68
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.00	37413.00
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic (In Rs)	-3.66	-3.15	-1.88	-6.81	-5.40	-0.28
	(b) Diluted						

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)




Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10.11.2023
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 30th September, 2023
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 30th September, 2023 in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

Place: Rajkot
Date: 10.11.2023

FOR, PARMAX PHARMA LIMITED


Dr. Umang Gosalia
Managing Director



PARMAX PHARMA LIMITED


Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2023

Sr. No.	Particulars	(In Rs. Thousands)	
		As at 30.09.2023 (Unaudited)	As at 31.03.2023 (Audited)
I.	Assets		
1	Non-current assets		
	(a) Property, Plant and Equipment	91124.46	95004.81
	(b) Capital work-in-progress	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Goodwill	0.00	0.00
	(e) Other Intangible assets	0.00	0.00
	(f) Intangible assets under development	0.00	0.00
	(g) Biological Assets other than bearer plants	0.00	0.00
	(h) Financial Assets	0.00	0.00
	(i) Investments	6.00	6.00
	(ii) Trade receivables	0.00	0.00
	(iii) Loans	2637.34	1865.84
	(i) Deferred tax assets (net)	0.00	0.00
	(j) Other non-current assets	1980.70	3961.40
	Total Non-Current Assets	95748.50	100838.04
2	Current assets		
	(a) Inventories	23882.50	43061.06
	(b) Financial Assets	0.00	0.00
	(i) Investments	0.00	0.00
	(ii) Trade receivables	22217.30	6227.45
	(iii) Cash and cash equivalents	1389.66	4067.91
	(iv) Bank balances other than(iii) above	0.00	
	(v) Loans	10991.05	21931.86
	(vi) Others (to be specified)	0.00	0.00
	(c) Current Tax Assets (Net)	0.00	0.00
	(d) Other current assets	172.00	0.00
	Total Current Assets	58652.51	75288.27
	Total Assets	154401012.1	176126.31
II.	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	44511.50	44511.50
	(b) Other Equity	-12655.03	14047.11
	Total Equity	31856.47	58558.61
2	LIABILITIES		
i.	Non-current liabilities	0.00	
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	54871.60	44790.90
	(ii) Trade payables	0.00	0.00
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
	(b) Provisions	0.00	0.00
	(c) Deferred tax liabilities (Net)	1410.68	1410.68
	(d) Other non-current liabilities	0.00	0.00
	Total of Non-Current Liabilities	88138.74	104760.19
ii.	Current liabilities		
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	0.00	0.00
	(ii) Trade payables	48746.89	46641.92
	(iii) Other financial liabilities (other than those specified in item (c))	0.00	0.00
	(b) Other current liabilities	8607.27	15037.08
	(c) Provisions	8908.11	9687.12
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Total of Current Liabilities	66262.27	71366.12
	Total Equity and Liabilities	154401.01	176126.31

FOR, PARMAX PHARMA LIMITED



Dr. Umang Gosalia
Managing Director
Place: Rajkot
Date: 10.11.2023**PARMAX PHARMA LIMITED**

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2023

(Amt. Rs. Thousands)

PARTICULARS	Half Year Period Ended on 30/09/2023	Half Year Period Ended on 30/09/2022	Period Ended on 31/03/2023
	Unaudited	Unaudited	Audited
(A) CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit After Extraordinary Item but Before Taxation:	-26702.15	-20206.69	461.23
Adjustments for:			
Depreciation	8510.44	9280.61	18785.72
Provision for Current Tax	0.00	0.00	1850.00
Current tax expenses relating to prior year			14.83
Provision for Deferred Tax Assets	0.00	0.00	-362.92
Operating profit before Working Capital changes	-18191.71	-10926.08	17382.12
Adjustments for changes in Working Capital:			
(Increase) / Decrease in Inventories	19178.56	759.53	-14536.06
(Increase) / Decrease in Trade & Other Receivables	-15989.85	3711.83	541.53
(Increase) / Decrease in Short term Loans and Advances	10768.81	4497.64	-2171.78
Increase / (Decrease) in Current Liabilities	-5103.85	-13351.89	-2126.42
Increase / (Decrease) in Tax Provisions	0.00	0.00	350.78
(Increase) / Decrease in Non Current Assets	1980.70	1980.70	3961.40
(Increase) / Decrease in Long term Loans & Advances	-771.51	-2125.62	-70.62
Cash generated from Operations	10062.86	-4527.81	-14051.16
Net Cash from Operating activities (A)	-8128.85	-15453.89	3330.96
(B) CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Fixed Assets	-4630.09	-5158.44	-9363.99
Net Cash from / (Used in) Investing activities (B)	-4630.09	-5158.44	-9363.99
(C) CASH FLOW FROM FINANCING ACTIVITIES			
Increase / (Decrease) in other Long Term Borrowings	10080.69	10558.93	-441.58
(Increase) / Decrease in Non Current Investment	0.00	0.00	0.00
Net Cash (Used in) Financing activities (C)	10080.69	10558.93	-441.58
Net Increase in Cash & Cash Equivalents (A + B + C)	-2678.25	-10053.40	-6474.61
Cash & Cash Equivalents at the beginning of the year	4067.91	10542.52	10542.52
Cash & Cash Equivalents at the end of the year	1389.66	489.12	4067.91

FOR, PARMAX PHARMA LIMITED


Dr. Umang Gosalia
Managing DirectorPlace: Rajkot
Date: 10.11.2023

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311,
Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)